"Dopamine Agonists/pharmacology"[MeSH] - Search Results

Year	Number of Results
1977	1
1992	11
1993	15
1994	126
1995	310
1996	329
1997	397
1998	358
1999	388
2000	378
2001	342
2002	337
2003	361
2004	324
2005	353
2006	390
2007	402
2008	351
2009	366
2010	315
2011	330
2012	319
2013	361
2014	284
2015	274
2016	232
2017	207
2018	226
2019	222
2020	187
2021	163
2022	95
2023	89
2024	28

1

The complex molecular pharmacology of the dopamine D₂ receptor: Implications for pramipexole, ropinirole, and rotigotine.

Ferraiolo M, Hermans E. Ferraiolo M, et al. Pharmacol Ther. 2023 May;245:108392. doi: 10.1016/j.pharmthera.2023.108392. Epub 2023 Mar 21. Pharmacol Ther. 2023. PMID: 36958527 Review.

2

Dopamine: Agonists and Neurodegenerative Disorders.

Khanam S, Siddique YH. Khanam S, et al. Curr Drug Targets. 2018;19(14):1599-1611. doi: 10.2174/1389450118666171117124340. Curr Drug Targets. 2018. PMID: 29149825 Review.

3

Dopamine receptor pharmacology.

Seeman P, Van Tol HH. Seeman P, et al. Trends Pharmacol Sci. 1994 Jul;15(7):264-70. doi: 10.1016/0165-6147(94)90323-9. Trends Pharmacol Sci. 1994. PMID: 7940991 Review.

4

Dopamine receptor partial agonists and addiction.

Moreira FA, Dalley JW. Moreira FA, et al. Eur J Pharmacol. 2015 Apr 5;752:112-5. doi: 10.1016/j.ejphar.2015.02.025. Epub 2015 Feb 25. Eur J Pharmacol. 2015. PMID: 25724788 Review.

5

Dopamine receptor agonists for Parkinson's disease.

Blandini F, Armentero MT. Blandini F, et al. Expert Opin Investig Drugs. 2014 Mar;23(3):387-410. doi: 10.1517/13543784.2014.869209. Epub 2013 Dec 9. Expert Opin Investig Drugs. 2014. PMID: 24313341 Review.

6

Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease.

Stocchi F, Fossati B, Torti M. Stocchi F, et al. Expert Opin Drug Saf. 2020 Sep;19(9):1155-1172. doi: 10.1080/14740338.2020.1804550. Epub 2020 Oct 3. Expert Opin Drug Saf. 2020. PMID: 32869676 Review.

7

The use of modern dopamine partial agonists in bipolar depression: is the evidence sound?

Serafini G, Nasrallah HA, Amore M. Serafini G, et al. Curr Med Res Opin. 2022 May;38(5):773-775. doi: 10.1080/03007995.2022.2059973. Epub 2022 Apr 12. Curr Med Res Opin. 2022. PMID: 35361016 No abstract available.

8

An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson's disease.

Ayuso P, Jiménez-Jiménez FJ, Gómez-Tabales J, Alonso-Navarro H, García-Martín E, Agúndez JAG. Ayuso P, et al. Expert Opin Drug Metab Toxicol. 2023 Jul-Dec;19(7):447-460. doi: 10.1080/17425255.2023.2249404. Epub 2023 Aug 24. Expert Opin Drug Metab Toxicol. 2023. PMID: 37599424 Review.

9

Computational study on new natural compound agonists of dopamine receptor.

Li H, Yang W, Xi J, Wang Z, Lu H, Du Z, Li W, Wu B, Jiang S, Peng Y, Liu J, Liu L, Zhang X, Feng J. Li H, et al. Aging (Albany NY). 2021 Jun 25;13(12):16620-16636. doi: 10.18632/aging.203180. Epub 2021 Jun 25. Aging (Albany NY). 2021. PMID: 34170848 Free PMC article.

10

Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Perez-Lloret S, Rascol O. Perez-Lloret S, et al. CNS Drugs. 2010 Nov;24(11):941-68. doi: 10.2165/11537810-000000000-00000. CNS Drugs. 2010. PMID: 20932066 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8,060 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8,060 results

Results by year